Caren van Roekel

83 Radioembolization 132. Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, et al. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival. Cardiovasc Interv Radiol. 2017;40(1):69-80. Epub 2016/10/16. 133. Jia Z, Jiang G, Zhu C, Wang K, Li S, Qin X. A systematic review of yttrium-90 radioembolization for unresectable liver metastases of melanoma. Eur J Radiol. 2017;92:111-5. Epub 2017/06/19. 134. Michl M, Haug AR, Jakobs TF, Paprottka P, Hoffmann RT, Bartenstein P, et al. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. Oncology. 2014;86(1):24-32. Epub 2014/01/10. 135. Kim AY, Unger K, Wang H, Pishvaian MJ. Incorporating Yttrium-90 trans- arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience. BMC cancer. 2016;16:492. Epub 2016/07/20. 136. Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, et al. Transarterial Y t t r ium- 90 Radi oembo li z a t i on Treatment of Patients with Liver- Dominant Metastatic Renal Cell Carcinoma. J Vasc Interv Radiol. 2017;28(2):254-9. Epub 2016/12/14. 137. Kuei A, Saab S, Cho SK, Kee ST, Lee EW. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World J Gastroenterol. 2015;21(27):8271-83. Epub 2015/07/29. 138. Lam MG, Louie JD, Iagaru AH, Goris ML, Sze DY. Safety of repeated yttrium-90 radioembolization. Cardiovasc Interv Radiol. 2013;36(5):1320-8. Epub 2013/01/29. 139. Zarva A, Mohnike K, Damm R, Ruf J, Seidensticker R, Ulrich G, et al. Safety of repeated radioembolizations in patients with advanced primary and secondary liver tumors and progressive disease after first selective internal radiotherapy. J Nucl Med. 2014;55(3):360-6. Epub 2014/02/12. 140. Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization. Liver International. 2017;37(1):101-10. Epub 2016/08/16. 141. Braat MN, Samim M, van den Bosch MA, Lam MG. The role of 90Y-radioembolization in downstaging primar y and secondar y hepatic malignancies: a systematic review. Clin Translat Im. 2016;4:283-95. Epub 2016/08/12. 142. Goebel J, Sulke M, Lazik-Palm A, Goebel T, Dechene A, Bellendorf A, et al. Factors associated with contralateral liver hypertrophy after unilateral radioembolization for hepatocellular carcinoma. PloS One. 2017;12(7):e0181488. Epub 2017/07/15. 2